Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2011-06-07
2011-06-07
Skelding, Zachary (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C514S825000
Reexamination Certificate
active
07955598
ABSTRACT:
A therapeutic agent for chronic arthritides diseases of childhood-related diseases, for example chronic arthritides diseases of childhood, Still's disease and the like, comprising an interleukin-6 (IL-6) antagonist as an active ingredient.
REFERENCES:
patent: 5670373 (1997-09-01), Kishimoto
patent: 5851793 (1998-12-01), Kishimoto
patent: 5888510 (1999-03-01), Kishimoto et al.
patent: 6428979 (2002-08-01), Kishimoto
patent: 6692742 (2004-02-01), Nakamura et al.
patent: 6723319 (2004-04-01), Ito et al.
patent: 7479543 (2009-01-01), Tsuchiya et al.
patent: 2002/0187150 (2002-12-01), Mihara et al.
patent: 2003/0236260 (2003-12-01), Shimojo et al.
patent: 2006/0292147 (2006-12-01), Yoshizaki et al.
patent: 0 628 639 (1994-12-01), None
patent: 0 783 893 (1997-07-01), None
patent: 0 791 359 (1997-08-01), None
patent: 0 983 767 (2000-03-01), None
patent: 1 074 268 (2001-02-01), None
patent: 2 147 443 (2000-04-01), None
patent: WO 95/09873 (1995-04-01), None
patent: WO-96/18648 (1996-06-01), None
patent: WO 9749428 (1997-12-01), None
patent: WO-98/13383 (1998-04-01), None
patent: WO-99/48523 (1999-09-01), None
patent: WO 2004/096273 (2004-11-01), None
Hoshino et al., J Rheumatol. Feb. 1998;25(2):396-8.
Horneff et al., “Treatment of refractory juvenile chronic arthritis by monoclonal CD4 antibodies: a pilot study in two children,” Annals of the Rheumatic Diseases, 1995, 54:846-849.
Reiter et al., “Treatment of rheumatoid arthritis with monoclonal CD4 antibody M-T151. Clinical results and immunopharmacologic effects in an open study, including repeated administration,” Arthritis Rheum., May 1991, 34(5):525-536. (Abstract, PubMed PMID:2025306).
Bendayan, J. Histochem. Cytochem., vol. 43, 1995, pp. 881-886.
Carroll et al., “Antagonism of the IL-6 Cytokine Subfamily—A Potential Strategy for More Effective Therapy in Rheumatoid Arthritis,” lnflamm. Res., vol. 47, 1998, pp. 1-7.
De Benedetti et al., “Interleukin 6 Causes Growth Impairment in Transgenic Mice through a Decrease in Insulin-like Growth Factor-I”,Journal of Clinical Investigation, vol. 99, No. 4, Feb. 1997, pp. 643-650.
De Benedetti et al., Arthritis and Rheumatism, vol. 52, No. 3, 2005, pp. 687-693.
Elliott et al., “Suppression of Fever and the Acute-Phase Response in a Patient With Juvenile Chronic Arthritis Treated With Monoclonal Antibody to Tumour Necrosis Factor-α (cA2),” British Journal of Rheumatology, vol. 36, 1997, pp. 589-593.
Hashkes et al., JAMA, vol. 294, 2005, pp. 1671-1684.
Hirata et al., J. Immunol., vol. 143, 1989, pp. 2900-2906.
Imazeki et al., “IL-6 functions in cynomolgus monkeys blocked by a humanized antibody to human IL-6 receptor”,International Journal of Immunopharmacology, vol. 20, pp. 345-357, 1998.
Keul et al., “A Possible Role for Soluble IL-6 Receptor in the Pathogenesis of Systemic Onset Juvenile Chronic Arthritis”,Cytokine, vol. 10, No. 9, pp. 729-734, 1998.
Lepore et al., “Study of IL-2, IL-6, TNF Alpha, IFN Gamma and Beta in the Serum and Synovial Fluid of Patients With Juvenile Chronic Arthritis,” Clin. Exp. Rheumatology, vol. 12, No. 5, 1994, pp. 561-565.
Mangee et al., “Cytokines in Juvenile Rheumatoid Arthritis (JRA)”,Cytokine, vol. 10, No. 6, Jun. 6, 1998, pp. 471-480.
Mihara et al., “Humanized Antibody to Human Interleukin-6 Receptor Inhibits the Development of Collagen Arthritis in Cynomolgus Monkeys”,Clinical Immunology, vol. 98, No. 3, Mar. 2001, pp. 3,19-326.
Oen et al., “Interleukin 6 and Autoantibodies in Juvenile Rheumatoid Arthritis,” J. rheumatology, vol. 20, No. 11, 1993, pp. 1949-1956.
Rooney et al., “Inflammatory Cytokine Responses in Juvenile Chronic Arthritis,” Br. J. Rheumatology, vol. 34, No. 5, 1995, pp. 454-460.
Takagi et al., Blockage of Interleukin-6 Receptor Ameliorates Joint Disease in Murine Collagen-Induced Arthritis,Arthritis and Rheumatism, vol. 41, No. 12, Dec. 1998, pp. 2117-2121.
Take et al., “Successful Treatment With Aurranofin in a Patient With Elderly-Onset Still's Disease,” J. Med., vol. 25, No. 6, 1994, pp. 393-397.
Wendling et al., “Treatment of Severe Rheumatoid Arthritis by Anti-Interleukin 6 Monoclonal Antibody,” The Journal of Rheumatology, vol. 20, 1993, pp. 259-262.
Yoshizaki et al., “Therapy of Rheumatoid Arthritis by Blocking IL-6 Signal Transduction with a Humanized Anti-IL-6 Receptor antibody”,Springer Seminars in Immunopathology, Springer, Berlin, Germany, vol. 20, No. 1/2, 1998, pp. 247-259.
Juvenile Rheumatoid Arthritis,The Merck Manual, 17thEd., Sec. 19, Chapter 270, p. 2398, 1999.
Office Action in corresponding Chilean Application 1239-2004, 8 pages.
Dosa, Laszlo, “IL-6 Receptor Antibody Shows Promise for Juvenile Rheumatoid Arthritis,” ACR 67thAnnual Scientific Meeting: Abstract 1070, Oct. 2003, 1 page.
Nishimoto et al., “Toxicity, Pharmacokinetics, and Dose-Finding Study of Repetitive treatment with the Humanized Anti-Interleukin 6 Receptor Antibody MRA in Rheumatoid Arthritis. Phase I/II Clinical Study,” The Journal of Rheumatology, 2003, 30(7):1426-1435.
Gallagher et al., “Juvenile rheumatoid arthritis,” Current Opinion in Rheumatology, 1999, 11:372-376.
Arkachaisri et al., “Use of Biologics in the Treatment of Childhood Rheumatic Diseases,” Current Rheumatology Reports, Current Science, Aug. 1, 2000, 2(4):330-336.
De Benedetti et al., “Is Systematic Juvenile Rheumatoid Arthritis an Interleukin 6 Mediated Disease?”, Journal of Rheumatology, Feb. 1, 1998, 25(2):203-207.
Fishman et al., “The Effect of Novel Polymorphisms in the Interleukin-6 (IL-6) Gene on IL-6 Transcription and Plasma IL-6 Levels, and an Association with Systemic-Onset Juvenile Chronic Arthritis,” Journal of Clinical Investigation, Oct. 1, 1998, 102(7):1369-1376.
Mangge et al., “Long-Term Follow-Up of Cytokines and Soluble Cytokine Receptors in Peripheral Blood of Patients with Juvenile Rheumatoid Arthritis,” Journal of Interferon and Cytokine Research, Sep. 1999, 19(9):1005-1010.
Yilmaz et al., “Cytokine Levels in Serum of Patients with Juvenile Rheumatoid Arthritis,” Clinical Rheumatology, Jan. 2001, 20(1):30-35.
Office Action dated Dec. 7, 2009, in corresponding EP 02 708 772.5, 7 pages.
Adams et al., “Update on the pathogenesis and treatment of systemic onset juvenile rheumatoid arthritis,” Curr. Opin. Rheum., 2005, 17:612-616.
Bellomo, R., “The Cytokine Network in the Critically Ill,” Anaesthesia and Intensive Care, Aug. 1992, 20(3):288-302.
Brewer et al., “Penicillamine and hydroxychloroquine in the treatment of severe juvenile rheumatoid arthritis,” New England J. Med., May 15, 1986, 314(20):1269-1276.
Choi et al,. “Serum Cytokine Profiles in Patients with Adult Onset Still's Disease,” The Journal of Rheumatology, 2003, 30(11):2422-2427.
Elliott et al., “Treatment of systemic juvenile chronic arthritis (JCA) with monoclonal anti-TNFα—Temporary control of systemic but not articular features of disease,” Arthritis Rheum., 1994, 37:S276, two pages.
Knulst et al., “Cytokine detection and modulation in acute graft vs. host disease in mice,” Mediators of Inflammation, 1994, 3:33-40.
Nowak et al., “Combination of Methotrexate and Prednizone Decreases Circulating Concentrations of Interleukin 1β and Interleukin 6 in Patients with Rheumatoid Arthritis: Poor Correlation of Cytokine Supression with Clinical Improvement,” International Journal of Immunopathology and Pharmacology, 1999, 12(1):13-21.
Taga et al,. “GP130 and the Interleukin-6 Family of Cytokines,” Annu. Rev. Immun., 1997;15:797-819.
Thompson et al., “Chemokine Receptor CCR4 on CD4+ T Cells in Juvenile Rheumatoid Arthritis Synovial Fluid Defines a Subset of Cells with Increased IL-4:IFN-γ mRNA Ratios,” J. Immunol., Jun. 1, 2001, 166(11
Iwamoto Masahiro
Minota Seiji
Miyamae Takako
Nishimoto Norihiro
Yokota Shumpei
Chugai Seiyaku Kabushiki Kaisha
Foley & Lardner LLP
Skelding Zachary
LandOfFree
Therapeutic agent for chronic arthritides diseases of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic agent for chronic arthritides diseases of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic agent for chronic arthritides diseases of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2619421